Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/ BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X For ...

Core Insights - BioHarvest Sciences Inc. has announced a new contract targeting the plant-based fragrance compound market, utilizing its proprietary botanical synthesis platform [1] - The contract focuses on a rare plant that is under threat from overharvesting and habitat loss, aligning with the company's commitment to sustainability [4] - The market for natural, plant-derived fragrance ingredients is experiencing growth due to increasing consumer awareness [1][3] Company Developments - The CEO of BioHarvest Sciences, Ilan Sobel, emphasized the significance of the new contract in the multi-billion dollar fragrance industry, particularly in the segment focused on natural plant-derived compounds [3] - The company has developed significant AI capabilities to identify the specific plant species for the fragrance compound, enhancing its discovery process [5] - The project will be executed in two stages, with strict NDAs in place for the first stage, which involves sourcing the plant and conducting tissue culture work [6] Revenue Potential - Stage two of the project will involve scaling up cell growth in bioreactors, aiming for cost efficiency and significant royalty margins [7] - The company aims to demonstrate the breadth of its botanical synthesis platform, which can produce various plant-based compounds, thereby impacting major billion-dollar industries [8]

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [6][22] - Gross profit rose by 53% to $4,600,000, representing a gross margin of 58.5%, up from 56.2% in the same quarter last year [22][23] - Net losses for Q1 2025 totaled $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [23][24] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA [6][10] - The Amazon channel represented 20% of the business, showing improvements in customer conversion and repeat purchase rates [6] - The CDMO services division has signed multiple customers, including a partnership with Tate and Lyle for developing next-generation plant-based sweeteners [16][17] Market Data and Key Metrics Changes - The company reported a significant increase in gross margins, attributed to scaling operations and cost efficiencies [7][8] - The rollout of new products, including superfood tea and coffee, is expected to capture additional market segments [10][12] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025 [18] - Strategic focus includes expanding the direct-to-consumer portfolio, investing in R&D for process improvements, and building AI-powered tools for CDMO services [19] - The company plans to launch new products targeting younger consumers and expand into the hydration and beauty markets [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute and deliver on the company's mission to democratize life-changing compounds [25] - The company is optimistic about the growth potential in the pharmaceutical sector, driven by increasing interest in non-GMO and plant-based compounds [72][74] - Management highlighted the importance of regulatory flexibility and the potential for significant revenue opportunities in the pharmaceutical market [73] Other Important Information - Cash and cash equivalents as of March 31, 2025, totaled $3,400,000, an increase from $2,400,000 at the end of 2024 [24] - The company raised $3,900,000 in debt financing during the quarter, primarily from existing investors [24] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - The transition to Phase two involves moving from solid media to liquid media for cell conditioning, expected to take six to nine months [28][30] Question: How long will it take to narrow down targets with Tate and Lyle? - Significant work is underway, with a comprehensive update expected before the end of the year [32] Question: Should we anticipate continued gross margin expansion? - Management expects continued improvements in gross margins alongside revenue growth [34] Question: How many products contributed to revenue in Q1? - The majority of revenue came from three product lines, with expectations to increase to four by Q2 [39][40] Question: Will marketing costs drop due to increased ad inventory? - The company is focused on reducing marketing costs as a percentage of revenue while exploring new channels [42][46] Question: Does the second quarter guidance include CDMO contributions? - Yes, it includes revenue recognition from existing projects and potential new catalysts [47] Question: How many CDMO programs can be run concurrently? - The company can handle five to seven projects at one time in the initial stages [51] Question: What is the timeline for the olive cell product? - The product is expected to launch in 2026, with a faster ramp-up anticipated due to complementary marketing strategies [84]

BioHarvest Sciences Reports First Quarter 2025 Financial ResultsFirst Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceMay 15, 2025 4:05 PM EDT | Source: BioHarvest Sciences Inc.Rehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March ...